nurix
therapeutics
present
annual
targeted
protein
degradation
summit
san
francisco
globe
newswire
nurix
therapeutics
nasdaq
nrix
company
developing
targeted
protein
modulation
drugs
today
announced
company
presenting
targeted
protein
degradation
tpd
summit
held
virtually
additional
details
presentation
targeted
protein
degradation
tpd
summit
session
robust
translation
towards
clinical
development
title
targeted
protein
modulation
harnessing
inhibiting
ligases
decrease
increase
protein
levels
presenter
arthur
sands
ceo
date
wednesday
october
time
edt
copies
slide
presentation
archived
available
investors
section
company
website
nurix
therapeutics
nurix
therapeutics
biopharmaceutical
company
focused
discovery
development
commercialization
small
molecule
therapies
designed
modulate
cellular
protein
levels
novel
treatment
approach
cancer
immune
disorders
leveraging
nurix
extensive
expertise
ligases
together
proprietary
libraries
nurix
built
deligase
integrated
discovery
platform
identify
advance
novel
drug
candidates
targeting
ligases
broad
class
enzymes
modulate
proteins
within
cell
nurix
drug
discovery
approach
either
harness
inhibit
natural
function
ligases
within
ubiquitin
proteasome
system
selectively
decrease
increase
cellular
protein
levels
nurix
wholly
owned
pipeline
comprises
targeted
protein
degraders
bruton
tyrosine
kinase
signaling
protein
inhibitors
casitas
lymphoma
ligase
regulates
cell
activation
nurix
headquartered
san
francisco
california
information
please
visit
http
contacts
investors
jason
kantor
nurix
therapeutics
jkantor
media
cherilyn
cecchini
lifesci
communications
ccecchini
